Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes

BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus–oocyte complexes retrieved from unstimulated ovari...

Full description

Saved in:
Bibliographic Details
Published inHuman reproduction (Oxford) Vol. 23; no. 3; pp. 504 - 513
Main Authors Shu, Yi-min, Zeng, Hai-tao, Ren, Zi, Zhuang, Guang-lun, Liang, Xiao-yan, Shen, Hong-wei, Yao, Shu-zhong, Ke, Pei-qi, Wang, Ning-ning
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.03.2008
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus–oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
AbstractList BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes.BACKGROUNDIn an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes.Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days.METHODSCumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 microM cilostamide or 50 microM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days.Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin.RESULTSBoth cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin.Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.CONCLUSIONSCombined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
BACKGROUND: In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS: Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 mu M cilostamide or 50 mu M forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS: Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS: Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were used to extend pre-maturation culture of immature human oocytes. METHODS Cumulus-oocyte complexes retrieved from unstimulated ovaries were continuously cultured under 20 µM cilostamide or 50 µM forskolin, alone or in combination for 6, 12, 24 or 48 h, respectively. Levels of intercellular gap junction communication (GJC) and maturational status were examined at these designated time points. Metaphase II oocytes obtained following 54 h biphasic culture (with meiotic inhibitors from 0 to 24 h, no meiotic inhibitors from 24 to 54 h) were subject to intracytoplasmic sperm injection and embryos were cultured for five more days. RESULTS Both cilostamide and forskolin delayed spontaneous meiotic progression after continuous culture with immature human oocytes. Combined treatment of cilostamide and forskolin significantly lowered the rates of germinal vesicle breakdown (GVBD) at 6, 12, 24 or 48 h after meiotic inhibitory culture, when compared with the control (all P < 0.05). A delay of 6 h for the loss of GJC was also observed under the combined treatment of cilostamide and forskolin. The fertilization rate was significantly higher under the combined treatment of cilostamide and forskolin than that of the control. Although the rates of oocyte maturation and embryo cleavage were similar among groups, there was a slight but non-significant increase in blastocyst formation rate with the treatment of cilostamide and forskolin. CONCLUSIONS Combined treatment of cilostamide and forskolin positively influences oocyte developmental competence by exhibiting a synergistic effect on the prevention of GJC loss and resumption of meiosis.
Author Shu, Yi-min
Ren, Zi
Wang, Ning-ning
Zeng, Hai-tao
Zhuang, Guang-lun
Shen, Hong-wei
Yao, Shu-zhong
Liang, Xiao-yan
Ke, Pei-qi
Author_xml – sequence: 1
  givenname: Yi-min
  surname: Shu
  fullname: Shu, Yi-min
  email: shuyimin@hotmail.com, 4Correspondence address. IVF Program, Department of Obstetric and Gynecology, Stanford University Medical Center, Palo Alto, CA 94304, USA. shuyimin@hotmail.com†These three authors contributed equally.
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 2
  givenname: Hai-tao
  surname: Zeng
  fullname: Zeng, Hai-tao
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 3
  givenname: Zi
  surname: Ren
  fullname: Ren, Zi
  organization: Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangzhou 510080, People's Republic of China
– sequence: 4
  givenname: Guang-lun
  surname: Zhuang
  fullname: Zhuang, Guang-lun
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 5
  givenname: Xiao-yan
  surname: Liang
  fullname: Liang, Xiao-yan
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 6
  givenname: Hong-wei
  surname: Shen
  fullname: Shen, Hong-wei
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 7
  givenname: Shu-zhong
  surname: Yao
  fullname: Yao, Shu-zhong
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 8
  givenname: Pei-qi
  surname: Ke
  fullname: Ke, Pei-qi
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
– sequence: 9
  givenname: Ning-ning
  surname: Wang
  fullname: Wang, Ning-ning
  organization: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20200445$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18216034$$D View this record in MEDLINE/PubMed
BookMark eNqF0s9rFDEUB_AgFbutHr3KIChexub3zBylVCsWPahQvIRM5g1NO0nGJCPuf2_WWfdQkJ4Skk8eL1_eCTrywQNCzwl-S3DHzm4WF2E-G8Axzh-hDeES15QJfIQ2mMq2JkSSY3SS0i3GZdvKJ-iYtJRIzPgGxYtxBJNTFcbK2CmkrJ0doNJ-qMYQ012YrK-Cr_INVA5syNZUEdLi5mzL8c6B6-M2-HIxwC-YwuzA511B65zOS4SqNKlLlWC2GdJT9HjUU4Jn-_UUfX9_8e38sr768uHj-bur2gghcm0aTCkfgI8CdxJrKaloaCNY34y47ZjWuO96CWA0k8Iw3uC-6RqujcBGc8FO0eu17hzDzwVSVs4mA9OkPYQlqaYEIFmJ4SFIcVuSFrzAl_fgbViiL59QlJCOEypoQS_2aOkdDGqO1um4Vf8yL-DVHuhk9DRG7Y1NB0cxxZj_7Z-tzsSQUoRRGZv1LvUctZ0UwWo3AWqdALVOQHlV33t1aOA__s3qwzI_SPelbcrw-4B1vFOyYY1Ql9c_1NdPXff5Wkgl2R82pNJn
CODEN HUREEE
CitedBy_id crossref_primary_10_1016_j_anireprosci_2014_06_026
crossref_primary_10_5653_cerm_2021_04413
crossref_primary_10_1007_s11626_015_9878_y
crossref_primary_10_1016_j_theriogenology_2022_04_014
crossref_primary_10_1016_j_theriogenology_2016_02_029
crossref_primary_10_1093_humrep_det086
crossref_primary_10_33590_emj_10310074
crossref_primary_10_1093_biolre_ioz114
crossref_primary_10_1017_S096719941700017X
crossref_primary_10_1186_s12958_022_00906_5
crossref_primary_10_1071_AN17895
crossref_primary_10_3390_ph14070684
crossref_primary_10_1016_j_repbio_2018_07_001
crossref_primary_10_1016_j_ejphar_2020_173293
crossref_primary_10_1016_j_theriogenology_2020_12_018
crossref_primary_10_1093_humupd_dmad023
crossref_primary_10_1186_s13048_023_01291_2
crossref_primary_10_1016_j_anireprosci_2016_09_003
crossref_primary_10_3389_fendo_2020_00548
crossref_primary_10_1016_j_livsci_2015_12_014
crossref_primary_10_1016_j_theriogenology_2014_07_042
crossref_primary_10_1093_humrep_den420
crossref_primary_10_1095_biolreprod_111_092858
crossref_primary_10_1186_s12958_018_0445_8
crossref_primary_10_1186_s13048_020_00704_w
crossref_primary_10_1016_j_theriogenology_2012_09_020
crossref_primary_10_1038_s41598_023_32677_3
crossref_primary_10_1080_15384101_2018_1471316
crossref_primary_10_1095_biolreprod_108_074450
crossref_primary_10_1016_j_anireprosci_2015_05_012
crossref_primary_10_1038_cdd_2017_134
crossref_primary_10_25259_JRHM_5_2020
crossref_primary_10_1002_jcb_26171
crossref_primary_10_1095_biolreprod_113_114132
crossref_primary_10_3389_fendo_2019_00464
crossref_primary_10_1095_biolreprod_114_118471
crossref_primary_10_1095_biolreprod_113_110577
crossref_primary_10_1371_journal_pone_0126801
crossref_primary_10_1007_s10815_024_03272_w
crossref_primary_10_1016_j_theriogenology_2020_12_009
crossref_primary_10_1093_humupd_dmx040
crossref_primary_10_1007_s12522_012_0134_9
crossref_primary_10_1111_rda_14021
crossref_primary_10_1016_j_theriogenology_2022_11_016
crossref_primary_10_1002_mrd_22307
crossref_primary_10_1016_j_theriogenology_2023_07_035
crossref_primary_10_1007_s43032_019_00137_x
crossref_primary_10_1071_RD12341
crossref_primary_10_1016_j_fertnstert_2008_12_110
crossref_primary_10_1093_molehr_gat075
crossref_primary_10_1016_j_fertnstert_2008_12_111
crossref_primary_10_1016_j_livsci_2017_01_013
crossref_primary_10_1093_molehr_gax032
crossref_primary_10_1111_rda_12667
crossref_primary_10_1016_j_theriogenology_2016_04_013
crossref_primary_10_1016_j_mehy_2018_05_015
crossref_primary_10_1016_j_theriogenology_2016_12_015
crossref_primary_10_1017_S0967199415000064
crossref_primary_10_1007_s10815_013_0061_7
crossref_primary_10_1016_j_ejphar_2020_173115
crossref_primary_10_1530_REP_18_0173
crossref_primary_10_1186_s12958_020_0566_8
crossref_primary_10_1016_j_theriogenology_2016_01_008
crossref_primary_10_1016_j_theriogenology_2013_04_012
crossref_primary_10_1093_humrep_dex262
crossref_primary_10_1371_journal_pone_0030649
crossref_primary_10_1093_humrep_dev083
crossref_primary_10_1210_me_2008_0320
crossref_primary_10_1016_j_theriogenology_2021_06_003
crossref_primary_10_1016_j_theriogenology_2019_09_034
crossref_primary_10_1093_humrep_dep104
crossref_primary_10_1007_s10815_017_0958_7
crossref_primary_10_1016_j_anireprosci_2018_11_002
crossref_primary_10_1093_biolre_ioab176
crossref_primary_10_3390_jdb12020010
crossref_primary_10_1051_e3sconf_202128503013
crossref_primary_10_1016_j_fertnstert_2008_10_016
crossref_primary_10_1016_j_ijbiomac_2023_129149
crossref_primary_10_3390_genes14101885
crossref_primary_10_1016_j_fertnstert_2023_02_010
crossref_primary_10_1093_humrep_dew020
crossref_primary_10_1371_journal_pone_0068456
crossref_primary_10_1002_rmb2_12640
crossref_primary_10_1007_s10815_018_1365_4
crossref_primary_10_1016_j_jevs_2020_103112
crossref_primary_10_1093_humrep_deq246
crossref_primary_10_1186_1471_2350_13_121
crossref_primary_10_1071_RD17335
crossref_primary_10_1530_REP_15_0606
crossref_primary_10_3390_toxics10070355
crossref_primary_10_25259_JRHM_7_2020
crossref_primary_10_1371_journal_pone_0247518
crossref_primary_10_1093_humrep_deu329
crossref_primary_10_5005_jp_journals_10016_1251
ContentType Journal Article
Copyright The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008
2008 INIST-CNRS
The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Copyright_xml – notice: The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008
– notice: 2008 INIST-CNRS
– notice: The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TM
8FD
FR3
K9.
P64
RC3
7ST
7U6
C1K
7X8
DOI 10.1093/humrep/dem344
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Environment Abstracts
Sustainability Science Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Genetics Abstracts
Engineering Research Database
Technology Research Database
Nucleic Acids Abstracts
Biotechnology and BioEngineering Abstracts
Sustainability Science Abstracts
Environment Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE
MEDLINE - Academic
Genetics Abstracts


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2350
EndPage 513
ExternalDocumentID 1441409241
18216034
20200445
10_1093_humrep_dem344
10.1093/humrep/dem344
ark_67375_HXZ_SK99NX56_6
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E4
.2P
.55
.GJ
.I3
.XZ
.ZR
0R~
1TH
29I
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
AAWDT
ABDFA
ABEJV
ABEUO
ABGNP
ABIME
ABIXL
ABJNI
ABKDP
ABMNT
ABNHQ
ABNKS
ABPIB
ABPQP
ABPTD
ABQLI
ABQNK
ABSMQ
ABVGC
ABWST
ABXVV
ABXZS
ABZBJ
ABZEO
ACCCW
ACFRR
ACGFS
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFQV
AFFZL
AFGWE
AFIYH
AFOFC
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIJHB
AJBYB
AJDVS
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
ANFBD
APIBT
APJGH
APWMN
AQDSO
AQKUS
ARIXL
ASAOO
ASPBG
ATDFG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AYOIW
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BSCLL
BSWAC
BTRTY
BVRKM
BZKNY
C1A
C45
CAG
CDBKE
COF
CS3
CXTWN
CZ4
DAKXR
DFGAJ
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EIHJH
EJD
ELUNK
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MBLQV
MBTAY
MHKGH
ML0
N9A
NGC
NLBLG
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OBOKY
OCZFY
ODMLO
OHT
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RIG
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCN
TCURE
TEORI
TJX
TLC
TMA
TR2
W8F
WH7
WOQ
X7H
X7M
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
6.Y
AASNB
AAYOK
ABQTQ
ABSAR
ACMRT
ADJQC
ADRIX
AFXEN
KC5
M49
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TM
8FD
FR3
K9.
P64
RC3
7ST
7U6
C1K
7X8
ID FETCH-LOGICAL-c555t-c70224de4f50960a662572753b7f0893aa0b9b6eeca365c3470b7974ac50ca453
ISSN 0268-1161
1460-2350
IngestDate Fri Jul 11 00:29:52 EDT 2025
Mon Jul 21 11:27:23 EDT 2025
Fri Jul 25 04:09:52 EDT 2025
Mon Jul 21 06:00:00 EDT 2025
Mon Jul 21 09:16:20 EDT 2025
Thu Apr 24 22:50:28 EDT 2025
Tue Jul 01 00:38:55 EDT 2025
Wed Aug 28 03:24:43 EDT 2024
Tue Aug 05 16:49:42 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords meiotic resumption
forskolin
human oocyte
cytoplasmic maturation
cilostamide
Human
Embryonic development
3',5'-Cyclic-nucleotide phosphodiesterase
Enzyme
Enzyme inhibitor
Esterases
Phosphoric diester hydrolases
Germinal cell
Phosphodiesterase inhibitor
Cilostamide
Ripening
Vertebrata
Mammalia
Hydrolases
Oocyte
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c555t-c70224de4f50960a662572753b7f0893aa0b9b6eeca365c3470b7974ac50ca453
Notes istex:D8807ACA3AEDA8C4971D11611D6FA01377207C87
ArticleID:dem344
ark:/67375/HXZ-SK99NX56-6
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/humrep/article-pdf/23/3/504/9543870/dem344.pdf
PMID 18216034
PQID 211941252
PQPubID 36115
PageCount 10
ParticipantIDs proquest_miscellaneous_70346360
proquest_miscellaneous_20809354
proquest_journals_211941252
pubmed_primary_18216034
pascalfrancis_primary_20200445
crossref_citationtrail_10_1093_humrep_dem344
crossref_primary_10_1093_humrep_dem344
oup_primary_10_1093_humrep_dem344
istex_primary_ark_67375_HXZ_SK99NX56_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-03-01
PublicationDateYYYYMMDD 2008-03-01
PublicationDate_xml – month: 03
  year: 2008
  text: 2008-03-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Human reproduction (Oxford)
PublicationTitleAlternate Hum Reprod
PublicationYear 2008
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
SSID ssj0016186
Score 2.2687037
Snippet BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,...
BACKGROUND In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,...
In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator, forskolin were...
BACKGROUND: In an attempt to allow for acquisition of oocyte cytoplasmic maturation, PDE3 specific inhibitor, cilostamide and adenylate cyclase activator,...
SourceID proquest
pubmed
pascalfrancis
crossref
oup
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 504
SubjectTerms Adenylyl Cyclases - metabolism
Adult
Biological and medical sciences
Cells, Cultured
cilostamide
Colforsin - pharmacology
cytoplasmic maturation
Drug Synergism
Embryonic Development - drug effects
Female
forskolin
Gap Junctions - drug effects
Gap Junctions - physiology
Gynecology. Andrology. Obstetrics
human oocyte
Humans
Medical sciences
Meiosis - drug effects
meiotic resumption
Oocytes - cytology
Oocytes - drug effects
Phosphodiesterase Inhibitors - pharmacology
Quinolones - pharmacology
Title Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes
URI https://api.istex.fr/ark:/67375/HXZ-SK99NX56-6/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/18216034
https://www.proquest.com/docview/211941252
https://www.proquest.com/docview/20809354
https://www.proquest.com/docview/70346360
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELfKJiEkhKDjEQbDSKhfWLYstpP24wSDwrQJaZ1U9UvkOI6ItiRVmwrKX8_5UacVVDy-RFFyeel-vtzZd79D6I3iMBchyfw-IdynIc983lezTaEIBQ8oobpc7OIyGl7Tz2M27nS-rVeXNOmR-PHbupL_0SocA72qKtl_0Ky7KRyAfdAvbEHDsP0rHZ-1yRhCdSRoeFlkZj0AfNH5jWrIY1cD3payqA1fM7yhsRNKTpbpbKm74GRt-pDmkShLzflpu_jVtVg2Nt_Q-rJm_l-xYmrSWIOjvqlAXJtguPq60Ha-8MvCIXEijY0Z8sJveO2WfYwRnBTtfPbCTmh_VDv-7aLamKfot4laR9LYVhoFfkgMz-zK-JpiYwsysmZJmelK_IuFN-xX8OnwebCTyZLQDUlQ0bTUCofQSTXRpu2vziUgrk7dQbshxBeq9cX7T-du-Uk1EbCErPC8Y_O0Y_MsRTNrr97wZXbVsPy-qpO8P-VzGGS56Y6yPXzRbszoIXpg4w98asD0CHVk1UV7pxVv6nKJe1hnBOulli66e2ETL7qo98VQnC8P8ait2Jsf6isc-flyD80sJnGd4zVMYsAadpjEdYUBk9hiEreY1HIOk3gNk-qGK0xijUlsMfkYXX84G70b-ravhy8YY40vYuU4ZpLminso4BHE4OBGM5LGeQD-M-dBOkgjKQUnEROExkEaQ9zLBQsEp4w8QTtVXclnCIs45lEs4yiLc0rCuH-Sqx4BhHIQTeWJhw5XGkqEJb1XvVduE5N8QRKj28To1kM9Jz41bC9bBbW6nRSf3agUyZglw_EkuTofDC7HLEoiD70GPPzpZgcbaHHSYaCsHWUe2l_BJ7HmZ54oakYK4UnooVfuLPwb1IIfr2S9ABEIBweE0e0S8L_XjIEeempQ2b6pxfjzrWf20b12nL9AO81sIV-Ch96kB3o0_QTGGevV
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+cilostamide+and+forskolin+on+the+meiotic+resumption+and+embryonic+development+of+immature+human+oocytes&rft.jtitle=Human+reproduction+%28Oxford%29&rft.au=Shu%2C+Yi-min&rft.au=Zeng%2C+Hai-tao&rft.au=Ren%2C+Zi&rft.au=Zhuang%2C+Guang-lun&rft.date=2008-03-01&rft.eissn=1460-2350&rft.volume=23&rft.issue=3&rft.spage=504&rft_id=info:doi/10.1093%2Fhumrep%2Fdem344&rft_id=info%3Apmid%2F18216034&rft.externalDocID=18216034
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-1161&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-1161&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-1161&client=summon